SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " ingredient " 100 found 🔀 AI-powered Shuffle
Sign in to save shuffle history.
New leaders appointed for IFF's Food Ingredients business
Mark Hotze and Thomas Hahlin Ahlinder will help guide the unit as it becomes a standalone company.
Former Miami Heat Forward Approves Klay Thompson Signing
NBA veteran PJ Tucker breaks down why the sharpshooter’s elite floor-spacing is the perfect ingredient to unlock the Miami Heat's offense alongside stars Giannis Antetokounmpo and Bam Adebayo.
Kelly Vlahakis-Hanks Keeps Science Green at ECOS
Chief Executive Kelly Vlahakis-Hanks maintains a keen focus on sustainable manufacturing at ECOS, the company her father founded 60 years ago, building upon his initial idea to create non-toxic alternatives for cleaning. Van Vlahakis, a chemist, founded the manufacturer of green cleaning products at a time when no one was paying attention to ingredients. “He […]
A new sunscreen ingredient is coming to a store near you. Here’s why that’s a big deal
A St. Louis dermatologist explains the sunscreen science behind bemotrizinol.
Naturally Sparkling: The Science Behind Pet-Nat Wine
This week’s Northern Express — sister publication of The Ticker — is the Ingredients issue, featuring stories about our farmers, growers, chefs, bakers, and winemakers. In the lattermost category, a few local wineries are trying their hands at a 500-year-old winemaking process, pétillant-naturel, or pét-nat. What makes it different from traditional wine styles are three main components: …
Doritos as farm-to-table snacks? Big Food, under duress, gets creative
Doritos in the classic nacho cheese flavor have 27 ingredients, including not just familiar ones but also a number of additives and preservatives.
Science Done Right: New Clinical Evidence Advancing Cardiovascular Nutrition
Discover the key findings from this landmark study and what they reveal about the next generation of clinical research shaping the vitamin K2 category.
BioVivo Science launches VeriPalmetto with fully traceable saw palmetto supply chain
The ingredient addresses growing demand for authenticated, US-sourced saw palmetto — with direct harvester relationships, standardised fatty acid profiles and rigorous batch testing to counter adulteration risks in the category
Candidates, voters, merch: Politics bingo ingredients are everywhere at Minnesota State Fair
Turn your State Fair visit into a hunt for politics bingo.
Scientists Have a Secret Ingredient for Better Concrete: Your Poop
In a sustainable future, nothing goes to waste…including human waste.
NJ Health Commissioner Dr. Raynard Washington Leads Cooking Class at Harvest
New Jersey Health Commissioner Dr. Raynard E. Washington joined RWJBarnabas Health at Harvest: A Farm to Community Center where we joined a wonderful group of seniors for an interactive cooking class. Commissioner Washington and registered dietitian Alyssa chopped and mixed Rainbow Grain Bowls using colorful, nutritious, local Jersey-grown ingredients.
Insight: Booming weight-loss drug demand in Brazil fuels thriving black market and health fears
When Brazilian customs agents opened jars of dulce de leche aboard a tourist bus arriving from Paraguay in April, they discovered hundreds of vials of tirzepatide, the active ingredient in the popular weight-loss drug Mounjaro, mixed inside the sweet spread.
The science behind the beauty business
Some of Europe’s industrial champions may be in retreat, but its cosmetics sector remains a global leader, buoyed by healthy demand, recognised brands and a reputation for innovation."The fact is, the science in cosmetics is better here in Europe than anywhere else in the world,” says Pierre Morvan, CEO of Technature, a private label cosmetics manufacturer located near Brest in France’s northwestern Brittany region. “You have to have good science in order to make the difference, and that is why we invest so much in research and innovation.”Across Europe, the beauty and skincare products sector supports an estimated 3.6 million jobs, including 265,000 employed directly in the industry, according to the Cosmetics Europe trade group.. Cosmetics production contributes an estimated €11 billion to the EU economy, and generated €30 billion in export revenue last year, a €400 million rise from 2024.Technature itself has a global footprint, supplying products for 1,500 brands in 65 countries. Its range of skin gels, facial masks, nail treatments and other products include natural ingredients and extracts derived from plants, such as seaweed, that are developed and refined through science-based analysis and testing.While industry projections point to sustained growth for the foreseeable future, driven by emerging economies and wider availability of exclusive brands that were once chiefly sold by high street retailers, the sector is not immune to the impact of geopolitics and trade wars. The Trump Administration’s tariff threats have dented cosmetics exports to the EU industry's largest overseas market. After the European Parliament approved the EU-US Turnberry Agreement in June, setting a 15% levy on many EU goods, the French Federation of Beauty Companies warned that “exports are falling sharply” and urged the EU to negotiate an opt-out for cosmetics.Technature’s CEO flags South Korea as an emerging competitor, partly due to its assertive marketing efforts. “I would have to say I am a little bit scared,” Morvan says, regarding the growth potential of the South Korean cosmetics industry. “This is why science and innovation are so important if Europe is to remain the leader.”With a workforce of 200, including biologists, chemists and other scientists, around 15% of Technature’s staff work in three research and development (R&D) labs. A similar number work in four quality control and assurance facilities, where science plays a crucial in ensuring product safety in a sector that is subject to the European Cosmetics Regulation.Educational exchange between industry and academiaIn recognition of Technature’s research and innovation, Morvan was selected as one of Brest’s ambassadors to Science Comes to Town (SCTT), a European initiative to strengthen communications and understanding between science and society. Brest is one of three coastal cities in the EU-funded programme, alongside Split (in Croatia) and Kiel (in Germany). From 7-11 September, Brest will host the EU TalentOn contest featuring 100 early-career researchers from across Europe.Morvan appreciates the value of engagement with educational and scientific institutions as well as the home community. For instance, Technature collaborates closely with university partners to enhance its in-house R&D. In addition, it invites students to its labs and sends its own researchers to local institutions. "We absolutely want the students to know what the industry is all about,” Morvan says, noting that seeing science in action can help young people “understand that they can do something real with science, to create something with what they are learning.” He says another important benefit: encouraging new generations of young people to consider a career in cosmetics.Community involvement also raises awareness about Technature and the skincare industry as a whole. “The public gains recognition of the innovative company that we are, and this is important for getting new customers,” Morvan says. One of its recent innovations — tiny, colourful cosmetic pearls that release skin moisturisers on application — was showcased at this year’s VivaTech event in Paris.Morvan holds a master's degree from the Brest Business School and studied animal production and biology in Brest at the University of Western Brittany (UBO), an SCTT partner, and at the University of Tours. He got his start in business in 2002, initially working on using seaweed as a raw material in the food industry before transitioning to cosmetics. Morvan has always been interested in connecting science and business, reflecting one the goals of SCTT to enhance public-private collaboration.The invitation to participate in SCTT was unexpected. “It was a surprise to get a call from the city of Brest saying that they wanted me on this programme,” Morvan recalls, adding that officials were drawn by his company’s R&D. “It's not only theory and science fundamentals. Our science is something that is applicable to the global market — and important for the community.”Science|Business, which connects policymakers, academics and industry through its news reporting, analysis and events, is an SCTT partner.
In 2022, scientists unveiled a wind-turbine material that could be recycled into gummy-bear ingredients. Four years later, where did the idea go?
A viral scientific breakthrough promised to solve wind energy's waste problem—but the gummy bears were never the real goal, and the hype outpaced what the lab could actually deliver.
Beauty-from-within surges with new science, finished products
Beauty-from-within makes a comeback while ingredient research shows benefits for bone and gastrointestinal health.
Will R.I. voters, elected officials continue investing in life sciences?
Rhode Island starts in a strong position and has the ingredients needed for innovation and growth. What we don’t have yet is a long-term commitment, writes the CEO of the RI Life Science Hub.
Business Monday: Hilo Pizza Co. serving up New York-style pies and slices that patrons can customize
Hilo Pizza Company has become a small staple of the Puainako Center since 2023, offering Hilo residents a taste of thin-crust pizza with a menu that features dough made from scratch with locally sourced ingredients.
The universe has plenty of hydrogen. So why is star formation collapsing?
Star formation across the universe has fallen dramatically over the past 4.5 billion years, but astronomers have uncovered a surprising twist: the supply of neutral hydrogen, a key ingredient for making stars, has barely declined. Using China’s FAST radio telescope and data from roughly 2.5 million galaxies observed by DESI, researchers found that star formation was about 2.5 times higher 4.5 billion years ago, while neutral hydrogen levels were only about 1.4 times higher.
Prostate health: Discover fucoidan at SupplySide Global
Fucoidans are innovative marine ingredients sought after by trusted nutraceutical brands. Ahead of SupplySide Global, Marinova – the global leader in fucoidan science – highlights new clinical findings paving the way for fucoidan to enter the growing men’s health category
IFF appoints 2 senior leaders to Food Ingredients business
Mark Hotze was named chief commercial officer, and Thomas Hahlin will oversee the Texturizing Solution business as senior vice president.
Reap the health benefits of fermented foods with these 9 recipes
How to eat more kimchi, yogurt and other fermented ingredients in fun and delicious ways.
PDO Chios Mastiha: Ancient Greek Tradition Meets Modern Science
From a legendary ingredient collected since ancient times to a versatile addition to the modern kitchen, PDO Chios Mastiha is bringing a distinctive taste of Greece to Canadian consumers. Produced exclusively in Mastichohora, in the southern part of Chios island, Mastiha owes its unique character to the region's particular soil and climate conditions, while its complex natural composition continues to attract scientific interest. Featured through the "Premium European Products: Better Knowledge,
Thinning hair? 6 hair growth ingredients actually backed by science
Here's what to look for before you invest in hair care.
Cherry Is the Hottest Skincare Ingredient of 2025 and Science Backs Its Incredible Skin Benefits
You have probably noticed that your skincare shelf is starting to look a lot like a farmers’ market. Strawberry serums, watermelon mists, blueberry masks – food-inspired beauty has been on the rise for a while now. But in 2025, the trend is shifting from cute packaging gimmicks to ingredients that actually deliver real results. And...
One of America's Most Widely Consumed Ingredients Linked to Metabolic Changes And Obesity
"It's not the oil itself ... It's what the fat turns into inside the body."
More Than a Charcuterie Board: A Mother and Daughter Build a Business Around Gathering.
The Bar Harbor Story is generously sponsored by Birch Bay Retirement Village. NORTHEAST HARBOR—Food’s ability to be a social cornerstone is one of the founding premises of one of Mount Desert Island’s newest, and perhaps most unique, endeavors in cuisine based catering. From intimate gatherings to large functions, Olive & Pearl creates charcuterie boards that can not only astound the tongue but also the eye. Many would agree that food can bring people together. In fact, culinary delights, and sometimes adventures, have been utilized as the centerpiece for social and business occasions of all kinds for centuries. Often times it even has the ability to start conversation, temper differences, and build new relationships. Settings can vary, from a multi-course sit down meal, a backyard barbecue, or a couple of bowls of chips and dip in front of a television, but the result can be the same. Humans come together, they share food, and the whole process is a catalyst for thought, communication, and a shared experience. Imagined and created by the mother and daughter team of Dr. Susan Scanlan (formerly MacCready) and Kayla Musetti, Olive & Pearl was started in June of this year and has been creating, delighting, and growing since. We gave the two an opportunity to answer some questions about themselves and their new venture. The love, passion, and pride for what they are doing and the fact that they are doing it as a mother and daughter team came through so strongly in their answers that we decided to present the question and answer session in its entirety. The Interview What did you do prior to Olive & Pearl? We’re a mother-daughter team, and food, family, and hospitality have always been a big part of our lives. Susan grew up in a large family in Pennsylvania, where the table was always at the center of everything. There were multiple dishes, little bites, stories, and plenty of conversation. Food was never simply about eating. It was about gathering, celebrating, and spending time together. After living in several Southern states, Susan relocated to Maine more than 20 years ago, and Maine has truly become home. She loves its sense of community, natural beauty, and connection to local food and makers. Professionally, Susan is a registered nurse and holds a doctorate in health administration. She has worked in a variety of clinical, nonclinical, and leadership roles and currently works as a faculty academic director. Building Olive & Pearl has been an exciting creative venture alongside her career. Kayla is also a registered nurse and works in the ambulatory surgery unit at Mount Desert Island Hospital. While healthcare is an important part of both of our professional lives, Olive & Pearl has given us an entirely different way to connect, collaborate, and create something together. Tell us about the business. Olive & Pearl is a mother-daughter charcuterie business centered around beautiful food, thoughtful presentation, and bringing people together. We create curated charcuterie boards designed for everything from intimate gatherings and dinner parties to weddings, showers, corporate events, boat days, and celebrations of all kinds. We think of our boards as more than food. They’re an experience and an invitation to gather, slow down, and enjoy time with the people around you. We’re intentional about quality ingredients, artful presentation, and personalization. Whenever possible, we also incorporate Maine-made and locally sourced products, including cheeses, jams, honey, seasonal produce, and baked goods. What inspired you to start Olive & Pearl? In many ways, Olive & Pearl grew out of something we had been doing our entire lives —bringing people together around food. We’ve always loved creating beautiful spreads for family and friends. There was something special about watching people gather around a table, graze, talk, laugh, and simply enjoy being together. Friends and family began telling us, “You should do this as a business,” and one day, we stopped laughing it off and started mapping it out. We realized we had an opportunity to combine our different strengths and create something that reflected what we both value: hospitality, creativity, quality, and connection. Charcuterie felt like the perfect expression of that. It’s beautiful and creative, but it’s also communal and approachable. At its heart, it brings us right back to where the idea began, a table filled with food and people gathered around it. Do you have a business partner(s)? Our business partner is each other! Olive & Pearl is truly a mother-daughter partnership, and building it together has been incredibly meaningful and sometimes hilarious! We know each other extremely well, which can be both a strength and, occasionally, a challenge. We have different personalities and strengths, but we’ve learned to lean into those differences and use them to our advantage. There’s a lot of trust between us, and we’ve learned how to communicate, collaborate, and occasionally laugh at ourselves along the way. We’re also building Olive & Pearl while continuing our careers in healthcare and education, so we’re taking things thoughtfully and growing the business one step at a time. We all have to start somewhere. One of the most rewarding parts has been having something that belongs to both of us. We get to learn from one another, celebrate the small wins together, and create something that we hope will become part of our family’s story for years to come. When exactly did you launch the business? Recently, in June 2026, we launched Olive & Pearl, turning an idea we had talked about for years into real business. It has been incredibly rewarding to watch something that started around our own family table and begin to find a place within the community. How is it going so far? How do you feel it has been received? It has been going very well, and we’ve been incredibly encouraged by how warmly Olive & Pearl has been received. As more people hear about us, our orders have continued to increase, and we’re seeing growing interest in boards for events and celebrations. It’s exciting to watch something that began as an idea between the two of us start to grow within the community. One of the most rewarding parts is hearing from customers after their events or seeing photos of our boards being enjoyed. Knowing that something we created became part of someone’s celebration is incredibly meaningful to us. Is there a brick-and-mortar location or is it all online? Olive & Pearl is currently an online business. We’re intentionally starting this way so we can build relationships with our customers, learn what they love, and grow thoughtfully. Our long-term dream, if the business continues to grow, is to eventually have a sit-down space where people can experience Olive & Pearl in person. Do you have any future plans if things go well/keep going well? Absolutely. For now, our focus is on continuing to grow Olive & Pearl, getting to know our customers, and becoming part of more celebrations and gatherings throughout the area. Long term, we would love to have our own physical space where people can come together and experience Olive & Pearl beyond the boards themselves. We can imagine a place that combines food, hospitality, creativity, and community. Ultimately, we want to build something that continues to grow while still feeling personal and connected to the people and community around us. Is there an aspect of the business that you really love? There are so many things we love about it, but the people and the connection are probably at the top of the list. We love creating something beautiful, but what really matters to us is what happens after we hand it over to the customer. We picture our boards on kitchen islands, at backyard gatherings, on boats, at weddings, or around a long dinner table—with people laughing, talking, and lingering a little longer. We also love the creative side. Every board is an opportunity to play with color, texture, shape, seasonality, and flavor. We don’t just want to fill a board, we want to curate an experience. And supporting local makers is especially meaningful to us. Whenever possible, we love incorporating Maine-made cheeses, local jams and honey, seasonal produce, and products from nearby bakeries and businesses. It allows us to showcase some of what makes Maine so special. Perhaps most importantly, we love doing this together. Building something as a mother and daughter has given us another way to spend time together, learn from one another, celebrate small wins, and create memories. Is there anything regarding any aspect of Olive & Pearl that you may think is important that is not reflected on the website? One thing that may not always come through online is just how personal this business is to us. Olive & Pearl isn’t something we created simply because charcuterie was popular. It grew very naturally from our family, our traditions, and the way we’ve always enjoyed gathering with people we love. There is a lot of heart behind every board. We think about the people who will be enjoying it, the occasion they’re celebrating, and how we can make the experience feel special. We also want people to know that we care deeply about supporting locals whenever possible. Using Maine products isn’t just about sourcing ingredients, it’s about telling a little story about where we live and the talented people who make and grow wonderful things here. Is there anything that we have not asked that you think is important/relevant that would like readers to know? We hope people see Olive & Pearl as more than just a charcuterie business. At its heart, it’s about gathering. Our goal is to make it easier for people to create those moments when everyone gathers around the table, conversations last a little longer, and people simply enjoy being together. We also hope people see the mother-daughter story behind the business. We’re building Olive & Pearl alongside our careers, one step at a time, and there is something incredibly special about creating a shared family legacy in the process. For us, success isn’t just about how many boards we make. It’s about becoming part of people’s special moments - birthdays, weddings, weekends with friends, quiet evenings at home, or a beautiful day on the Maine coast. If one of our boards helps people put down their phones, linger a little longer, laugh a little more, and enjoy the people around them, then we feel like we’ve done exactly what we set out to do. All photos courtesy of Olive & Pearl. LINKS TO LEARN MORE Olive & Pearl website Olive & Pearl Facebook Olive & Pearl Instagram RECENT PRESS RELEASES AND BRIEFS To see all the press releases, click here. To see our news, click here. For the full archive, click here. All of these are on our dedicated website. [ ](https://barharborstory.substack.com/p/pemetic-students-share-thoughts-on) [ Pemetic Students Share Thoughts on Declaration of Independence Oct 22 ](https://barharborstory.substack.com/p/pemetic-students-share-thoughts-on) [ Read full story ](https://barharborstory.substack.com/p/pemetic-students-share-thoughts-on) [ ](https://barharborstory.substack.com/p/fall-festival-at-the-noreaster-for) [ Fall Festival at the Nor’Easter for Mount Desert Nursery School, October 24. Oct 22 ](https://barharborstory.substack.com/p/fall-festival-at-the-noreaster-for) [ Read full story ](https://barharborstory.substack.com/p/fall-festival-at-the-noreaster-for) [ ](https://barharborstory.substack.com/p/explore-career-opportunities-where) [ Explore career opportunities where you make a difference for Maine’s natural resources—and the people who enjoy them. Oct 22 ](https://barharborstory.substack.com/p/explore-career-opportunities-where) [ Read full story ](https://barharborstory.substack.com/p/explore-career-opportunities-where) [ Cranberry Isles Comprehensive Plan Committee Oct 22 ](https://barharborstory.substack.com/p/cranberry-isles-comprehensive-plan) [ Read full story ](https://barharborstory.substack.com/p/cranberry-isles-comprehensive-plan) [ ](https://barharborstory.substack.com/p/community-school-hosts-a-pancake) [ Community School Hosts a Pancake Breakfast Fundraiser October 25! Oct 22 ](https://barharborstory.substack.com/p/community-school-hosts-a-pancake) [ Read full story ](https://barharborstory.substack.com/p/community-school-hosts-a-pancake) HELP SUPPORT THE BAR HARBOR STORY When we started The Bar Harbor Story, we didn’t know if anyone would read it. But you showed up. You shared. You sent tips. Now—over 400,000 views every month later—it’s clear: people here care about their community and each other. We’ve kept everything free because news should never be out of reach, but every one of our stories takes time to write, and your support keeps The Bar Harbor Story going. If you value our work, please consider a paid subscription, a founding membership, or a sponsorship. It truly helps us cover one more meeting, tell one more story, shine one more light. Even $5 a month makes a difference. Click here to become a one-time supporter now. Thank you so much for being here. Founding member information can be found here. Have questions about sponsorships? Just send Shaun an email at sfarrar86@gmail.com, he’d love to hear from you. Subscribe Share Bar Harbor Story Share Leave a comment
Sundar Pichai: Google’s Frontier Imperative, Compute Scarcity Dilemmas, Future AI Products and Businesses
Alphabet CEO Sundar Pichai has little patience for doubts about Google’s willingness or capacity to compete at the frontier of AI. His company’s latest Gemini 4 Argon model — long-promised and recently delivered — beats OpenAI and Anthropic’s latest public models on coding, math, science, and knowledge-work benchmarks and has placed Google’s AI back among the world’s best. Amid chatter that Google was fine with good-enough lightweight ‘Flash’ models, Pichai pushed back hard against any suggestion that company is limiting its research ambitions. “We won’t do it any other way,” he told me in a Big Technology Podcast interview recorded this week at Google’s Mountain View headquarters. Pursuing cutting-edge research is costly for Google, requiring compute and chips that otherwise could be sold at a high markup by its cloud business. But Pichai said allocating resources to frontier AI development is “ground zero” for Google. “Our cloud business is at any given moment in time forgoing short-term revenues because we are making compute trade-offs to support frontier AI development,” Pichai told me. In our conversation, we discussed Argon (which Pichai says processed three times as many tokens as Gemini 3 in the 72 hours after launch), AI’s role in developing better models, the AI interface of the future, competition with OpenAI, Google’s partnerships with Anthropic and Apple, data centers in space, and the nature of his optimism. You can read the full conversation, lightly edited for length and clarity, below, or listen to it on Apple Podcasts, Spotify, YouTube, or your podcast app of choice. Alex Kantrowitz: Google is back at the frontier with Gemini 4 Argon, which beats OpenAI’s and Anthropic’s public models on benchmarks spanning coding, math, science, and knowledge work. The conventional wisdom was that Google had given up on the frontier to focus on fast, good-enough models for its products. That was wrong? Sundar Pichai: Very wrong. Look, we are so committed to being at the frontier. It’s in our DNA. We won’t do it any other way. We’ve been thinking about the AI frontier for well over a decade now. The frontier is very dynamic. It’s very competitive. It’s very exciting. I couldn’t be more pleased with how Argon has come together. We took our time with it. We made sure we tested it safely and deployed it carefully. We took a bit longer than our other models, given its capabilities. Across the board, be it for agentic work, knowledge work, coding, creative tasks, Argon is one of the really good frontier models. The first 72 hours since we launched, it’s almost up to 25 trillion tokens used, which is about three times what Gemini 3.0 had in the first 72 hours. And we are capacity constrained as we are serving it. Excited, but there are always areas….. You know, the frontier is very dynamic, and you have to keep evolving the models. There are areas which we can see we need to improve as well. We’ll be at work on all of that as well. Which areas? On any given model, Argon would be across the board better at everything if you just look even two months back. But the space is so evolving. Even on coding, for example, there are pockets where we know we need to do better, and there’s clear feedback. We’ll make it better. The argument for standard models is that they’re already good enough to build great products, with the frontier valuable only for certain tasks. Meta built Muse with good models rather than the best, and Google could put standard models into Maps, Gmail, and Search. Why isn’t that sufficient? It’s definitely not how I have thought about it at all. We are deeply committed to driving the state of the art and actually pushing where this technology can go, all the way from transformers. That’s a journey we’ve been on. You will see us continue to do that. When you’re at the frontier, you get an earlier look into the emerging capabilities, earlier than others, which helps you better prepare for the future. We are fortunate to have a wide set of opportunities across consumer and enterprise. Some of our cloud customers, for sure, want the model at the frontier. The frontier models will be better at developing the next set of models in an era of recursive self-improvement. I would argue it matters there. Internally, we have definitely seen a steep point of inflection by deploying Argon to our developers. It definitely tackles problems which our previous models could not do. Being at the frontier puts you at the innovation frontier and helps you drive that as well. There is room for models of all sizes and capabilities. That’s why we did Flash, Flash-Lite, etc. I agree with you that you can develop very good product experiences with not necessarily the most frontier model, because they tend to be slower and more expensive too. But we care about the Pareto frontier, and we’re committed to doing all of that. You said developing frontier models gives you a look at what’s coming. What do you see on the horizon? What makes this moment so exciting is you build something which you think is a culmination of months of work, and you put it out. You already see clear headroom ahead. We’ve all been working on these agentic, long-horizon capabilities, but clearly the frontier is going to have multiple of these agents working together to do things. That’s an example of an exciting paradigm underway. It’s also clear to me that users, both in consumer and enterprise, will have access to some multi-agent framework for them, working all the time doing things. It feels like a moment of infinite possibilities. Sergey Brin said one of Argon’s core innovations was relying more on the model to help develop the model. Yet incidents involving OpenAI’s bots breaking containment and Google’s bots accessing a site they shouldn’t have suggest these systems still aren’t perfectly aligned. Isn’t there reasonable cause for concern about accelerating toward recursive self-improvement? There are three parts to your question. Let’s first talk about RSI itself. You’re right, Sergey mentioned RSI being a critical contributor as we are developing Argon. But to be very clear, today, in a continuum, we are pretty far from the end state of RSI or something like that. The right way to describe it is you have RSI loops along with AI researchers in various aspects of model development. You almost have agents helping AI researchers in some automated way work together to build these models. It’s good to at least understand where we are today, and it’s super exciting. I expect that continuum to keep making progress as we go into next year. The second question is around safety. Security comes from defense in depth. You’re talking about alignment, obviously. We all are doing a lot of work to make sure the models are as aligned as possible. But it’s an active area of research, and there are clear gaps. That’s not the only thing we rely on. You have the work you do on alignment, but beyond that, we put a lot of effort into real-time monitoring as these models are working. Making sure you have good telemetry into what’s happening so that you can intervene in real time if you see unexpected behaviors. How you do that, the architecture with which you do that, how you make sure it’s all sandboxed and isolated in a way that it can continue doing its job during real-time monitoring — these are all areas of investment. Obviously, when we deploy these models, giving customers, enterprises, control, both with real-time monitoring, but their ability to decide where they deploy, what type of data which models ever have access to, etc. All that work is very, very important, and we are doing a lot of that. As an industry, we need to constantly up our game and take the time to do all this stuff, including dedicating the compute required to make sure you can safely deploy these models. The third part is: Is it all enough? This is why there are a lot of conversations in the industry, and I think it’s reasonable to be worried. The right way to approach something you worry about is early on thinking about what more we can do. As an industry, you’re definitely seeing increased levels of work on alignment, testing for safety, etc., as we deploy these models. The next step would be developing better standards so there are cross-industry standards of how we do these things, including the ability to evaluate using independent evaluators. If you look at areas like financial controls, we have accounting standards, we have independent auditors. Those are all the next natural steps for us as an industry to work toward, and regulation will end up playing a role as we go through all of that as well. Google pursues both language models and world models, while some other AI companies like OpenAI have focused more heavily on LLMs as the path to AGI. Why is world-model research important to you? As humans, you obviously perceive the world around you, and you’re taking all those inputs. Making sure these models are able to understand the laws of physics, simulate the world in high fidelity. All that, I think, are key enabling blocks for intelligence. We are working across all possible applications of this. Take an area like robotics. It’s not an accident: If you look at embodied reasoning benchmarks, Argon is state of the art. That all comes from our experience building world models. Inherently, I would expect there will be architectures which will converge all of this in the future. But for us, we view this as, today, this jagged frontier that is intelligence. We want to be at the frontier of all the possible approaches, and that will help us both drive better research, better insights, and develop a much better AGI model, is how we think about it. Some people argue Google should focus on selling its computing resources rather than using them for AI research. Cloud wants to sell compute at a high markup, while researchers need a very big computer to build the best models. How do you balance those demands? Ground zero for us is making sure we are investing in the compute that’s needed to be at the AI frontier. In 2015, I set the company to be AI-first. AI is that key horizontal ingredient across everything we do, all the way from Search to Cloud to Waymo. That is ground zero for us, making sure both for research and developing the models that we have enough compute needed. Beyond that, we have these independent businesses which each have their own long-range plans. They’re using those long-range plans to project forward, and we plan for compute for all of them. The cloud team, they have a business and they have a projection and they have demand signals. They have committed contracts. With that help, we can plan on a long-term compute trajectory for them. We’re fortunate to have this wide set of opportunities. There’s no company in the world which isn’t making trade-offs at any given moment in time. But the first principles we operate on is making sure we have enough compute to invest in the frontier, and that’s non-negotiable, and everything else works on top. Remember, we are building our own compute, our own data centers. There are long lead times. The compute we have today is a function of decisions I made in 2024. Even if you think back to a year from today, last year the agentic coding takeoff hadn’t happened. Today, obviously, when you sit and look at anything, everyone is short—not just us, other companies—and everyone wishes you had two times what you had planned for. That comes with the territory. At any given moment in time, we are planning for what we would need two to three years out in the future. You’re going to find some decisions you make may look suboptimal two years out, depending on where the state of the art is. I don’t spend too much time thinking about it. The way I think about compute allocation is making sure Google DeepMind, both for research and frontier model development, is cutting edge in terms of compute access. After that, we plan for all our businesses. It’s great we can provide our compute to other people too, like we have done. It allows us to scale that up, get real tests for it in the widest application set possible, test it in the real world, and make sure we are at the cutting edge of technology at every layer of our AI stack as well. Ben Horowitz relayed on a podcast that Andy Jassy had said compute was sold out until 2028. Are you seeing the same thing? If today a customer is coming out and asking us for compute in ’27, that is incredibly difficult to do. Even last year we went out and leased some short-term compute to accommodate some customers and help them out. But yes, we are all dealing with similar timelines. Every major technology shift seems to involve overbuilding, from railroads to fiber. Do you think that’s happening here? It depends on the time frames you’re looking at. This level of build, if I take a long enough time frame, it makes complete sense to me. We are at early stages of the most consequential technology ever, and this is not like fiber. It’s not dark. We are using it. We are capacity constrained on a daily basis. The applications, the underlying technology is improving rapidly. But running a company, the way I work through the moment is you look at your demand signals. You look at your committed revenue opportunities that you’re getting in the form of contracts. You balance that with the underlying technical capability, or internally you balance how we are using it internally, the model trajectories. Based on all that, you take a disciplined approach—a confident, aggressive, but disciplined approach—to plan out compute. But when you talk about the broader economy as a whole, you’re having people operate with various levels of risk. I focus on what I can control as a company and plan through it. If your question is, can there be an overbuild? Yes, because you can have some constrained components. Remember, what matters is a set of everything you need to build out that compute. Memory, electricity, electricians…. Land. Like 2,000 components or more. You could get constrained at some point. There could be things which cause bottlenecks, and then you could have overbuilds. There could be external shocks to the economy. There are macro risks. All that is possible at any given time. But am I confident that the compute we are planning for, we will have uses for it given enough time? Absolutely, yes. I was in the room when you said AI would be as profound as fire and electricity. If you believe that, shouldn’t you give researchers the biggest possible computer, even at the expense of today’s cloud profits? We’re all doing some form of that. Our cloud business is at any given moment in time forgoing short-term revenues because we are making compute trade-offs to support frontier AI development. What you’re seeing is true already. But you want to be thoughtful. Even our AI researchers have some constraints, which are also good. That’s what inspires creativity. That’s what helps you come up with a more efficient algorithmic breakthrough, maybe to use less memory. What we are committed to is to invest what’s needed to stay at the frontier. OpenAI President Greg Brockman told me a few months ago that the ideal AI product might have no interface at all—just as natural as conversation. What do you think the interface looks like in the age of AI? Computing historically has been humans adapting to computing. With AI, it’ll be the other way around. The technology will adapt seamlessly to how humans live and go about their day-to-day life. You want to be able to speak to that AI when you want to. It has context. It can be persistently running somewhere, give you continuity. You’re not dealing with a lot of complexity. It’s natural. All that makes sense to me. That doesn’t mean it won’t have any interface, however. Nowadays, even on my phone, Gemini voice models are so good. I can just press the microphone button. I can just ramble. That’s why we call it Rambler. I can ramble. It intelligently corrects with my personal context. Even my friends’ names, weird names, it gets it right, even if it first guesses it wrong. It’s amazing. I’m not going in, backspacing, editing once I finish saying it. It’s remarkable how good it’s gotten. But there are going to be moments you will need an interface. You may want to entertain yourself. You may want to watch a video. You may ask your AI to create something, and you want to watch it, consume it. The way I think about it is, you want it to be as seamless and as natural as possible, and that you are not doing the hard work adapting to whatever the interface is. The technology is adapting to how you’re working at any given moment in time. When I asked Sam Altman about competition from Google, he argued that OpenAI was building AI-native products and implied Google was bolting AI onto existing ones. Do you accept that framing, and can a “bolt-on” compete with an AI-native product? First of all, it’s a very dynamic moment. We are all pushing each other. OpenAI has pushed us as a company too. This is not just we are doing something to them. Far from it. Yes, Google went into its own version of a code red too. In the AI moment, all of us have to respond with varying levels of urgency at any given moment in time. We are constantly building new products as well. Gemini was built from the ground up as a product—the Gemini app I’m talking about. Or tomorrow, as all of us are adapting to agents, are you bolting agents onto ChatGPT, or are they building it natively? How would you think about that? You can always put these questions back. I don’t think of it that way. I think of it as you want to build world-class product experiences that are AI-native and they are winning. Some of it is adapting products, some of it is rethinking new experiences. They will all be part of how you approach this moment. How do you expect to make money from these AI interfaces? If an agent recommends a product and I buy it, should it take a cut of the sale, even if that’s disclosed? I’m going to put enterprise aside. Consumers are going to increasingly value this technology. Take software developers today. Developers are willing to pay for these coding models because it really helps make them more productive. Nobody would want to code the way they were coding three years ago, or even the same time last year. When you’re delivering value, there’s value to be had. I’ve never seen examples where consumer products really scale to billions of users, where people are using it intensely, and haven’t had monetization to go along with it. If you’re providing value to people, there is inherent value to be had. The nature of it may change. You’re asking a scenario in which agents are doing stuff for you. At the end of the day, you will have commercial needs. The agents need to fulfill those commercial needs. The providers on the other side are going to see value in that. There’s going to be some mechanism by which it gets fleshed out. That’s what an efficient system does. But what matters is that you’re building those world-class consumer experiences. I promised myself one product feature request: Can you make Gemini-powered search in Gmail as good as searching Gmail through ChatGPT? What’s going on here? One of the exciting things we announced recently is the unified Gemini agent for enterprise, and we’re bringing that to consumers. These are persistent agents which run 24/7 in the cloud. We’re spinning up a micro VM effectively for every query, and from the runtime, the harness, the model—it’s all a headless service. It’ll work everywhere, and it has your context with you. You can address this agent whether you’re in Workspace, in Search, in Gemini. Agents are going to drive this unification from a customer experience, which people are looking for. When you have a broad product portfolio and you’re moving forward fast, there are always areas where you’re moving forward faster than some other areas. That’s valid feedback. But we are putting a lot of time and effort into making sure, as we build out our agentic experience, that unification and that capability works well across all these services. People have asked where Google’s equivalent of Muse or Dots is. Do you anticipate creating a new product to compete with them? Our goal with Gemini is to be a personal, proactive, and powerful assistant. That’s what we are working toward. You saw us describe the early versions of it at Google I/O this year with Spark. Effectively, already, if you open the Gemini app as a Pro or an Ultra user, you see Chat and Task, and they start giving you that agentic experience. With Argon now, that capability is dramatically accelerated. What we announced recently in our enterprise event, we are bringing that to consumers as well. Soon in Gemini, you will be able to ask something, and it’s a continuum. You don’t need to think about whether you’re asking a chat or an agentic task. It’ll just automatically do the right thing, and it can work persistently in the background securely and get things done for you. Already, empirically, when I look at what’s coming into Gemini in our app, last year you would have tagged them and most of them would have been chats. But a steadily growing percentage is already agentic tasks in Gemini. Yes, we are going to bring personal agents to our consumers. It’ll work in the Gemini app. It’ll work in Google Search. It’ll work in Gmail. You can address it, call it, etc. We want to make sure we’re getting it right. It’ll be powered by Argon, and we are very excited to bring it to our users. Google has invested and committed tens of billions of dollars to Anthropic. What do you see in Dario Amodei that makes you want such a deep investment and partnership? Very early on, when we looked at the founding team of Anthropic, it was very clear to us this was a world-class team which was involved in some of the earliest GPT models. We were quickly able to assess that they would be at the frontier. We’ve always tried to identify and partner with companies which would be at the cutting edge of technology. We’ve done that with SpaceX. We’ve done that with Anthropic. That’s what we saw, and we had a chance to partner. Is your partnership with Apple to license Gemini for Siri expanding, contracting, or standing still? For both us and Apple, that partnership was about translating the capabilities of AI into better experiences for users. I thought Apple has done a phenomenal job of incorporating—they customize these models and build it into Siri—and it’s been great to see the reception. We are committed to doing more. You’re going to do more with them? There’s nothing specific to comment, but it’s a partnership. It’s working well. What have you learned so far about the feasibility of data centers in space? It’s a very exciting project. Projects like this remind me—I still recall that moment in the desert for the DARPA Grand Challenge, watching the Stanley car compete in it, which ended up being the basis for Waymo. With all these technologies, you’re at a moment in time where it looks a bit like sci-fi, but 10 to 20 years down the line, it’s actually working in a meaningful way. I feel the same in space. We’ve always believed in betting big on these technologies. Quantum has been a great example of it. We’re probably 10 years into the journey. Waymo, we are almost 20 years into the journey. Space, we are two to three years into the journey. It’s clear to me that it’s an approach which will make a lot of sense in the future. Being in sub-synchronous orbits with 24/7 access to the most abundant form of energy we have access to will make a lot of sense for this exponential increase in compute that we are going to need. Having said that, this is a challenging project. The team has disciplined milestones. It was a super exciting milestone to send the TPUs up to space. Sometime, as we are speaking, we are expecting a “hello world” moment from them. I look forward to seeing that happen, and we’ll continue investing here too. You previously said 25% of the code written within Google was written by AI. What’s the number today? That number in our world today is meaningless in the sense that every part of what we now touch is influenced by AI deeply. What we are tracking with Argon, for example, it’s been a point of inflection. People are using Argon to really go tackle complex projects, including projects which affect millions of lines of code. In the four weeks since we have launched Argon, we have seen a 30% increase in CLs, and more importantly, almost a similar increase—a one-third decrease in rollbacks. People are writing code more productively and better code with it. We are tracking it with newer metrics now. How are you dealing with opposition to data centers? If you can’t build in the U.S. the way you want to, where else do you go? We’re very committed to building our data centers very responsibly. When I look at our largest data centers in some of the communities where we have been the longest, I visit them, I talk to people. There are people who come and tell us their kids have gone to college because of our investments in these communities, and we’ve grown in those communities. To me, this is about doing it right. Engaging with the communities early, doing it transparently. We are committed to making sure we are bringing incremental power, and we cover 100% of the cost of our power needs for these projects. It’s understanding the impact on neighborhoods and making sure you’re working thoroughly to address them. Done rightly, you can continue making progress. But we are constantly taking feedback into account. I do worry not everyone operates the same way. People have been surprised by data centers showing up in their backyard. Those are all important. As an industry, we should continue to do better. But part of the reason, in a 20-year time frame, we are thinking about things like data centers in space is making sure we are able to put these data centers where maybe the trade-offs will be different. What unproven area of AI is Google working hardest to crack? Is it continual learning—getting models to keep updating after release—or something else? There are multiple parallel paths. You saw with Argon we have a million output tokens. With our Gemini models early on, we had a one-million context window on the input side. These are all examples of breakthroughs we are constantly working on. How do you think about synthetic data? How do you think about continual learning? How do you think about more efficient architectures? We do dedicate a meaningful percentage of our compute to these research bets too. It always goes hand in hand, including our world models. Those are all bets we are placing. Sometimes, as part of these bets, there are ideas that emerge which just make their way into the mainline models. Maybe we don’t fully talk about it, but we have multiple steps in these areas. Working in technology requires optimism that building something will improve the world, but those bets can leave real consequences when they fail. I recently returned to a town in El Salvador where enthusiasm for Bitcoin had given way to unfinished construction and something resembling a ghost town. How do you maintain the optimism you spoke about in your Stanford commencement address while accounting for those risks? I genuinely have a deep conviction that improving technology and improving access to technology makes people’s lives better. It’s been my personal experience in my life, out of which comes that deep conviction, optimism. But with that, I’ve always felt humanity’s journey is always about working hard to harness that technology to make it work well for society. The optimism is not an optimism that you just build whatever you want, whenever. You work hard to make sure you’re building technology in the service of humanity, to make the human condition better. That’s got to be the defining goal as we are approaching it. With that framework, I’m very, very optimistic. We are in very early stages of the kind of progress that we are going to see on many areas. We’re all talking about areas like healthcare. A lot of the progress is ahead. The ability to make things in a fundamentally cheaper way on many things where things have been getting expensive for a long, long time, discovering new materials, etc., which really bend the curve—it’s tough to step today and understand the impact of all that, but they’re going to be very profound. I’m very optimistic, but we have to be rightfully concerned about all the ways this technology can go wrong. Sundar, I know you don’t do many of these. Thank you. Thanks, Alex. Appreciate it.
NASA-backed scientists turn plastic waste into edible cookies
Scientists have engineered yeast to turn PET plastic and agricultural waste into ingredients for protein-rich, 3D-printed cookies called µBites. Developed partly for NASA’s Deep Space Food Challenge, the system can produce proteins, fats, vitamins, and even vanilla flavoring from waste materials. Researchers hope the unusual technology could eventually help address both plastic pollution and food insecurity, while also supplying food in extreme environments such as deep-space missions.
RFK Jr. proposes rule to increase food ingredient oversight
The health secretary's proposal would overhaul a 1958 law that allows companies to self-affirm ingredients are safe
IFF Food Ingredients leadership team adds Hotze, Ahlinder
Mark Hotze is chief commercial officer while Thomas Hahlin Ahlinder is senior vice president, texturizing solutions.
Scientists want to 3D print houses on Mars with the help of yeast
Mars is a terrible place to build a house. It’s bitterly cold, blasted by radiation, and a near vacuum. Not to mention that the building materials, even for a modest shelter, could spend months hurtling through space before construction begins. But they don’t have to. In a study publishing September 10 in the journal Chem Circularity, researchers developed a recipe that could one day be used to 3D print houses on Mars. The recipe combines Martian rocks with Earthly ingredients: gelatin and yeast. Once dried and hardened, this living building material is as strong as low-grade concrete and can be broken down, recycled, and brewed again for new construction.
Ennature Biopharma Advances Women’s Health Science With Fast-Acting Shatavari and Sustained-Release Ginger
NOIDA, India, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Ennature Biopharma is expanding the clinical evidence for its Aspargize and Gingeren botanical ingredients, addressing two distinct areas of women’s health: menopause and menstrual health. The botanical formulations pair Shatavari for menopausal support with sustained-release ginger for menstrual comfort. The findings come amid growing interest in evidence-based women’s health solutions and ahead of World Menopause Month and SupplySide Global in O
3 Ingredients That Made The Coney a Success
The Coney took over the Detroit Opera House on Sept. 26. Here are the main takeaways from the all-star comedy event.
Massachusetts mom builds healthy muffin business during pandemic
Melissa Bermudez, co-founder and CEO of Unrefined Foods, turned her passion for baking into a business offering frozen, whole-grain muffins made with clean ingredients.
Will PENN Entertainment (PENN) Beat Estimates Again in Its Next Earnings Report?
PENN Entertainment (PENN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
We think of comets are harbingers of destruction. But it turns out they may be the reason life on Earth exists at all | BBC Sky at Night Magazine
Science has strengthened theories that the ingredients for life could have been brought to Earth by comets impacting into our home planet.
BioVivo Science secures organic certification for US facility and broccoli seed ingredient
The firm has secured organic certification for its Indiana botanical extraction facility and BrocoVio O broccoli seed ingredient, strengthening its US-made organic ingredient offering ahead of SupplySide Global
Health Canada recognises Saccharomyces cerevisiae as a source of resveratrol and yeast beta-glucan
Regulatory update supports the development and licensing of fermentation-derived health ingredients in Canada
Baton Rouge General's Health Tip of the Week: Another sugar substitute raises heart concerns
Sponsored by Baton Rouge General Cutting back on sugar? Take a peek at the ingredient label before reaching for a sugar-free treat. Recent research has raised questions about xylitol, a sugar alcohol found in products like gum, candy and baked goods. Higher blood levels of xylitol were linked to a greater risk of heart attack […]
Britain's digital health future depends on more than AI. It depends on trust.
Britain’s digital health future depends on more than AI, with trust emerging as the critical ingredient for successful transformation.
Science Must Move Faster Than Social Media
I have bought produce, cooked it, sold it, specified it, promoted it, walked fields with growers, stood in packing houses, worked with distributors and watched chefs turn raw ingredients into something people want to eat.
Magic mushroom ingredient takes the fight out of aggressive fish
A psychedelic compound found in magic mushrooms appears to have an unexpected effect: calming highly aggressive fish. Researchers discovered that low doses of psilocybin significantly reduced aggressive attacks in mangrove rivulus fish without disrupting their normal social interactions. The findings suggest psilocybin may selectively calm escalating aggression rather than simply suppressing all behavior.
RosCept Capsules Introduces Ros Cept Multi-Ingredient Dietary Supplement for Brain Health, Memory and Concentration
RosCept dietary supplement features Magnesium Beta Hydroxybutyrate, Calcium Beta Hydroxybutyrate, and Sodium Beta Hydroxybutyrate in a focused BHB formulation.Wilmington, DE, Oct. 05, 2026 (GLOBE NEWSWIRE) -- RosCept has announced the introduction of RosCept, a multi-ingredient dietary supplement formulated with three mineral beta-hydroxybutyrate (BHB) compounds: Magnesium Beta Hydroxybutyrate, Calcium Beta Hydroxybutyrate, and Sodium Beta Hydroxybutyrate. Official Website: https://roscept.shop/
Catching up with sleep health supplements: A roundup of the latest science
Sleep has moved from a lifestyle concern to a core measure of health, as inadequate sleep affects a substantial share of adults and often occurs alongside chronic stress, undermining health, well-being and performance across sleep-wake cycles and life domains.
Trump officials propose new requirements for food additives and ingredients
U.S. health officials want food manufacturers to provide more information about new additives and ingredients. Under a proposal announced Monday, food companies would have to notify the Food and Drug
Scientists discover vanilla’s hidden healing potential
Scientists have discovered that vanillin, the compound that gives vanilla its distinctive flavor, has powerful properties that could help fight infections, reduce inflammation, and promote wound healing. The inexpensive, widely available ingredient could one day become an important component of advanced wound treatments and regenerative medicine.
The Cost of Overlooking Generative AI in Entertainment -
By Sirius McDonell Writer/Reporter As the years go by, generative AI, or Gen AI, has started to become a staple in online spaces. You can ask it to write an essay for you, have it figure out a recipe from ingredients you have on hand or even talk to it as if it were your […]
Hebrew University scientists discover way to create real dairy proteins from plants
The discovery would thus help overcome a major hurdle in producing real dairy proteins without cows, paving the way for more sustainable dairy ingredients and less climate change.
Vibram Making A Focus On Outsoles A Growth Business
New partnerships for Italian-based Vibram with Nike, Brooks, Norda, Arc'teryx, Altra and others puts the footwear ingredient maker in the forefront
Squishies are everywhere. Burns and safety concerns are rising.
As squishy toys boom, reports of burns, leaks, and explosions are raising new questions about their safety and ingredients.
New FDA rule may require food manufacturers to disclose new additives
U.S. health officials want food manufacturers to provide more information about new additives and ingredients.
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
With a detailed data drop that AstraZeneca’s R&D chief described as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become a flagship biologic in chronic obstructive pulmonary disease (COPD). In detailed results from the late-stage Oberon and Titania trials—first teased in March and detailed in full at the European Respiratory Society Congress in Barcelona this week—the drugmaker laid out the extent of its IL-33 inhibitor’s potential to reduce moderate and severe exacerbations in a wide range of COPD patients still struggling with those “lung attacks,” as AstraZeneca’s Sharon Barr, Ph.D., called them, despite using standard-care inhaled therapy. In the headline results, a 300 mg dose of tozorakimab given once every four weeks curbed those moderate and severe exacerbations in the studies’ primary population of former smokers by 29% in the Oberon study and 34% in Titania. In the overall population of both current and former smokers, these reductions were 30% and 29%, respectively, versus placebo and inhaled standard of care. The benefits also extended to clinically meaningful exacerbation reductions in all prespecified patient subgroups and specifically turned up promising signals in patients across a range of blood eosinophil counts, with Barr telling Fierce that “it’s the details that make this even more exciting than the high-level results that we’ve already shared.” In fact, during AZ’s tozorakimab poster presentation at the ERS 2026 Congress this past weekend, attendees were so enamored by the data that event organizers had to encourage people to clear the room and look at the other presentations on offer, Barr said in an interview. “I think it really speaks to the fact that there is a lot of buzz around these data because the entire respiratory community has been so desperate for new therapies for these patients,” she explained. The respiratory disease continues to represent a “staggering unmet medical need,” Barr said, highlighting the COPD exacerbations that the Oberon and Titania studies homed in on, which she added carry a greater mortality risk than a heart attack. “When a patient has a severe exacerbation, only about half of them are still alive within three and a half years,” she pointed out. As for tozorakimab specifically, Barr christened the molecule “an AstraZeneca science success story,” harkening several years back to the point at which researchers began to explore IL-33 as a driver of respiratory disease, and COPD in particular. At the same time, “there was still so much that wasn’t understood,” she admitted, highlighting the insight that IL-33 signals through both ST2 and EGFR through the RAGE pathway, a discovery Barr attributed to AstraZeneca's own scientists. Understanding the need to tackle both pathways in COPD—and aware of competitor candidates in the hopper, including one that bound ST2—the company ultimately had to make some “courageous decisions,” Barr said. These included taking a prior COPD molecule offline and going back to the drawing board to reinvent its potential IL-33 label “to make sure that we had a molecule that could block signaling through both arms of the pathway, through both the reduced form and the oxidized form, knowing that we wouldn’t be first, but striving to be best.” “When we put [tozorakimab] into the clinic, we firmly believed that we had a differentiated molecule, and we saw the other molecules blocking just ST2 or partially blocking IL-33, unable to deliver two positive pivotal studies in COPD,” Barr explained. “We kept marching forward because we believed our molecule was differentiated, and now I think we have the clinical validation that supports that.” Ultimately, AstraZeneca finds itself on much better footing these days when it comes to potential biologic rivals to tozorakimab in COPD. Sanofi and Regeneron’s Dupixent, for instance, is approved to treat COPD exacerbations in patients with high eosinophil counts, but not low ones. Meanwhile, the future has become cloudier for other next-gen IL-33 candidates from Sanofi and Regeneron, as well as Roche, which have suffered trial flops in recent years. One other potential ingredient for AstraZeneca’s success in its duo of studies was that the company was “ambitious in the trial design, willing to look at an all-comers population,” Barr said, “and willing to enroll the most severe patients.” Prior studies for would-be biologics rivals in COPD “avoided enrolling” those patients, she pointed out. She also highlighted the Big Pharma’s painstaking design of exacerbations in its trial, which “gave us a very rigorous readout,” and pointed to “the extra effort and investment” the company put in to understand the effect of mucus plugs in patients. Barr described mucus production as a “key feature in disease diversity,” noting that mucus plugs—obstructing clumps of mucus that block patients’ airways—are associated with worse outcomes in COPD. In its data announcement, AstraZeneca noted that an integrated analysis of Oberon and Titania found tozorakimab “demonstrated a reduction in patients’ mucus plug score,” with the pharma claiming its biologic is the first to deliver such results in a broad COPD population. “So being able to reduce those mucus plugs, we expect, is an important part of driving benefit for patients who are living with COPD,” Barr said. Again touching on the breadth of the study populations, Barr added that tozorakimab “worked across all eosinophil levels in both current and former smokers across all levels of lung function,” which she suggested “really simplifies decision-making for clinicians, and it allows them to offer therapy to the broadest possible patient population.” In the highest patient eosinophil count group, tozorakimab helped chart a 43% reduction in exacerbation risk, which Barr stressed were “unprecedented data.” In the mid-level group, AZ’s drug delivered a 23% reduction and, in the lowest group, a 34% reduction in eosinophils, which Barr said suggests efficacy “in all patient subgroups.” As for AZ’s recent guidance upgrade on the medicine’s sales opportunity, the lift from a $3 billion to $5 billion range to $5 billion plus was informed by multiple factors, Barr said, including the fact that “in 2024, there were multiple competitors, and there aren’t anymore.” Additionally, “we know that this is a massive unmet medical need, and this is a really incredible set of data that we think will be very convincing to the clinical community,” Barr said. Looking ahead to a potential evolution of the COPD treatment landscape, Barr noted that most patients start treatment in the community with an option like a triple therapy, and for them, having an option like AstraZeneca’s inhaler Breztri will remain a “really important part” of that journey. But of the patients uncontrolled on triple therapy, which Barr described as “about half of them today,” just a “small fraction” are currently eligible for biologic therapy, which she emphasized AstraZeneca is working to change. Understanding that COPD is not a “one-size-fits-all” disease, AstraZeneca is also looking at its antibody drug Tezspire for patients with T2-driven disease, and the company continues to think about new mechanisms for tackling COPD through both systemic and inhaled drugs, Barr said.
Tate & Lyle strengthens climate ambition with updated science-based targets to reduce greenhouse gas emissions
Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, announced updated science-based targets to reduce greenhouse gas emissions (GHG) across its operations and supply chain. The new targets, which have been validated by the Science Based Targets initiative (SBTi) as consistent with reductions required to limit global warming to 1.5°C above pre-industrial levels, apply to Tate & Lyle’s expanded global footprint and supply chain following i...
PLT Health Solutions Brings Its Clinically Supported Branded Ingredient Platform to Vitafoods Asia
PLT Health Solutions, Inc. will exhibit for the first time at Vitafoods Asia, 2-4 September in Bangkok, Thailand, bringing its portfolio of more than 30 clinically supported branded ingredients to Asian brand owners and product developers. A major focus at the show will be the company's joint health and mobility portfolio. PLT will bring next-generation Kinexa™ Joint Longevity Complex to the Asian market for the first time. PLT introduced Kinexa™ in 2016 and has continued to develop the ingredie
Darling completes sale of sausage casings business to SARIA
Sale positions company for continued growth and value creation potential while optimizing portfolio and reducing debt.
Food Science Pilot Plant internship helps student find passion and gain experience
The University of Illinois Food Science Pilot Plant offers space for food processing companies to test new ingredients and technologies. And it gives students real-world experience to prepare for food science careers.
Eating less of common ingredient early in life may slash cancer risk decades later
Researchers found that early-life sugar rationing in post-war Britain correlated with lower cancer risk and slower aging roughly 50 years later.
CHANDO Group Showcases Chinese Beauty Science at COSMETIC 360, Debuts Fatigue-Aging Research on Global Stage
/PRNewswire/ -- CHANDO Group featured its five brands and latest advances in cosmetic ingredient research at the 12th edition of COSMETIC 360, organized by...
Your weather app runs on satellites, supercomputers and a retired science teacher who walked to his rain gauge at 7 a.m. every day for 50 years
The forecast on your phone has a secret ingredient: 8,700 volunteers with a thermometer. Meet the Frenches, a family in Gouverneur, N.Y. Ray monitored the stats for 50 years before his son took over. The 11-year-old granddaughter is next.
A Good Gut Feeling Starts with Strong Science
Digestive health is evolving beyond basic gut support as consumers increasingly connect the microbiome to broader wellness goals
Arizona babies take a bite out of research
Like many parents, Megan Rivas wants to give her 6-month-old daughter, Monroe, a healthy start, and one of the ways she’s going about it could make a big difference for more than just her daughter. Rivas is among dozens of parents across the Valley feeding their babies an unexpected research ingredient — avocados — as part of an Arizona State University College of Health Solutions study called Guac & Grow.
Scientists turn one of the hardest plastics to recycle into high-performance engine lubricant
Researchers have discovered a way to turn notoriously difficult-to-recycle PVC plastic into a key ingredient used in high-performance lubricants such as engine oil. The technique could give mountains of plastic waste a valuable second life while making lubricant production more sustainable.
Raising the Bar offers spirited history lessons
Once a month, at Hogwash Whiskey Den in downtown Spokane, historian Renée Cebula takes a roomful of students through centuries of American and global history that trace the wars, immigration, tariffs, and changing tastes that have helped determine what ingredients end up in her students’ glasses.
‘It’s devastating’: The US-Canada trade war is putting protein on the menu
Attention, protein maxers: One of your highly coveted ingredients is taking center stage in the escalating trade war between the United States and Canada.
Yuka's French CEO's routine: Saying 'no,' long lunches, biking to work
Julie Chapon is the CEO and cofounder of Yuka, an app that scores food and cosmetics according to their ingredients. Here's a day in her life.
Health Brief: The fight over ultra-processed foods
The Trump administration is weighing a federal definition of ultra-processed foods as RFK Jr. pushes a broader crackdown on ingredients tied to chronic disease
'Healthy' food labels may not mean what shoppers think
Opting for low-fat foods and drinks may seem like the best option, but it may pay to look at the rest of the ingredients list.
Booming Weight-Loss Drug Demand in Brazil Fuels Thriving Black Market and Health Fears
By Luciana Magalhaes SAO PAULO, Aug 31 (Reuters) - When Brazilian customs agents opened jars of dulce de leche aboard a tourist bus arriving from Paraguay in April, they discovered hundreds of vials of tirzepatide, the active ingredient in the popular weight-loss drug Mounjaro, mixed inside the ...
Early life exposure to a beloved food ingredient is linked to anxiety in adulthood: study
Mississippi couple takes on Gatorade, Powerade with new sports drink
A Mississippi couple launched a clean-ingredient sports drink company after struggling to find healthy options for kids.
The Culinary Director at a Unique California Restaurant Reveals the Key Ingredients Behind Its ‘Needle-in-a-Haystack’ Business Model
Deborah Mullin oversees a complex operation at Little Saint, the plant-based restaurant in Healdsburg, California.
Lallemand Bio-Ingredients to spotlight science-driven ingredients at Vitafoods Asia 2026
Lallemand Bio-Ingredients, Health Ingredients, a global leader in fermented functional ingredients for human health and nutrition, will showcase its latest science-backed ingredients at Vitafoods Asia 2026, taking place September 2-4, 2026, in Bangkok, Thailand
P2 Science Announces Appointment of Brian Freedman as Vice President, Marketing & Communications
/PRNewswire/ -- P2 Science, Inc., a leading green chemistry company transforming sustainable feedstocks into high-performance ingredients for beauty, personal...
Reap the health benefits of fermented foods with these 9 recipes
How to eat more kimchi, yogurt and other fermented ingredients in fun and delicious ways.
Wooree Green Science Introduces LipoPrime™ Liposomal Ingredients to the U.S. Market with a Data-Driven Approach to Performance and Quality
Wooree Green Science Co., Ltd., a leader in advanced liposomal delivery technologies, announced that its LipoPrime™ liposomal ingredient platform is now available to U.S. dietary supplement and functional nutrition brands.
SupplySide Global Brings Together Ingredient and Supplement Ecosystem for Discovery, Education and Business Acceleration
LAS VEGAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SupplySide Global , the world's leading trade show and conference for the supplement, food, and bev...
Popular erectile dysfunction pill may deliver additional boost to aging men
Tadalafil boosted muscle precursor cell survival in a lab study, but researchers say the active Cialis ingredient also delayed mature muscle development.
Tomatoes Contain an Invisible Ingredient With Surprising Effects on Liver Health
A tomato contains a hidden ingredient that the eye cannot see, and it may be just as important to liver health as the red pigment that made the fruit famous.
You Have the Power to Become the Master of Your Own Reality—and One Neuroscientist Knows How to Unlock It
It’s easier than you’d think—you just need one key ingredient.
5+ Best Dermatologist-Recommended Vitamin C Products in 2026
Seeing dull, uneven skin? This ingredient can help.
Burgers Have Meat and Vegetables. Why Aren’t They Considered Healthy? A Dietitian Explains
Registered dietitian Erin Palinski-Wade reveals the ingredients and cooking styles that give this beloved dish such a bad rap.
'The Social Reckoning' review: Aaron Sorkin's follow-up to 'The Social Network' is missing some key ingredients
A whistleblower reveals hard truths about Facebook in this sequel, which opens Friday.
Vibrant Ingredients Names Marie Wright Chief Science & Innovation Officer
Technical and innovation leader joins Vibrant to integrate capabilities and drive customer-focused growth...
CJ CheilJedang sets Singapore hub for APAC seasoning business
CJ CheilJedang has opened a Global Technical Center in Singapore to expand its food seasoning ingredients business in the Asia-Pacific region. The company held
Health Without Compromise
At IFT FIRST, experts share how food and ingredient companies are meeting demand for healthier products without compromising taste, texture, or value.
The science behind the 2026 Cyclospora Outbreak
This summer, a common salad ingredient became the center of a major foodborne illness outbreak across the United States. The Food and Drug Administration (FDA)…
Arjuna Natural to spotlight women’s health innovation and Ashwagandha Quality at SupplySide Global
Arjuna Natural, a leader, manufacturer, and innovator of standardised botanical extracts, will spotlight its award-winning women’s health portfolio and latest ingredient research at SupplySide Global in Las Vegas, NV, booth 6519, including new research on Rhuleave-K, a turmeric and boswellia combination developed to support fast-acting relief from PMS symptoms and lower back pain
Just a Handful of This 1 Ingredient Will Add More Healthy Fat and Protein to Your Meals, Dietitian Says
In TODAY.com’s Expert Tip of the Day, a dietitian shares her easy trick to add even more nutrients to her favorite meals.
CPHI Milan 2026: Clinical data drives hair, mood, heart & cognitive health ingredients
Customers are increasingly opting for human data over hype. In this space, CPHI Milan 2026 will convene pharmaceutical and nutraceutical players who are
Catching up with healthspan and lifespan supplements: A roundup of the latest science
Research on supplementation and aging is advancing quickly, helping to supplant “live longer” language with more nuanced claims based on closer examination of biological mechanisms that might help people live better for longer if they test out in human clinical trials.
Gateway Health Alliances to discuss GLP-1 product innovation at SupplySide Global
The US botanical ingredient supplier will be exploring weight management, metabolic health and nutritional support for consumers discontinuing GLP-1 medications at this year's show
Natural Field Expands NF TriSolve® Platform Into Sleep Wellness With Science-Driven Nutraceutical Solutions
/PRNewswire/ -- Natural Field, a technology-driven nutraceutical ingredient solutions provider, announced the expansion of its NF TriSolve® branded...
Explosive Intensification for Hurricane Polo
Several ingredients came together off the Pacific coast of Mexico to generate one of the strongest storms the eastern Pacific basin has ever seen.
St. Charles Park District: Building confidence, one Science experiment at a time
Column: Making soft, stretchy slime or dabbling in crafting Halloween-themed science experiences, there’s always a secret ingredient that instructor Lisa Lombardi brings to the table: Positivity, writes Melissa Rubalcaba Riske for the St. Charles Park District
Why you should check the ingredients of your açaí bowl
Beneath all that fruit and crunchy granola, are açaí bowls actually as healthy as they seem? Here's what to know.
The Rock's protein-heavy post-workout smoothie may not be right for everyone
A post-workout protein shake that Dwayne "The Rock" Johnson swears by packs 70 grams of protein powder, creatine and a surprising rice ingredient into one smoothie.
Nexira spotlights menstrual health ingredient BloomEase and ViNitrox vascular data at SupplySide Global
New clinical findings show ViNitrox improves Flow-Mediated Dilation by 41% versus placebo — while Nexira enters the longevity segment with NU4LIFE and VinOgrape Plus targeting mitochondrial and microbiome health
New ceratiq® Science Expands Skin Health Benefits to Include Sensitive Skin and Dermal Density
/PRNewswire/ -- PLT Health Solutions, Inc. today announced new clinical research on ceratiq® Phytoceramides that expand the ingredient's benefits beyond...
PDRN skin care: What the science really says about 2026’s hottest ingredient
For the second article in Cosmetics Business’ ‘Bench to bottle’ series, Rinki Pramanik investigates the science behind PDRN, and if this trending ingredient is just an attractive INCI name, or offers meaningful results